Benzinga | Jan 27, 2022 07:35AM EST

Morgan Stanley Maintains Overweight on Abbott Laboratories, Lowers Price Target to $151

Morgan Stanley maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $157 to $151.